Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer This investment positions France at the forefront of …